Department of Radiation Oncology, West Virginia University, Mograntown, WV, USA.
Department of Radiation Oncology, New York Methodist Hospital, Brooklyn, NY, USA.
J Gynecol Oncol. 2015 Jan;26(1):19-24. doi: 10.3802/jgo.2015.26.1.19. Epub 2014 Oct 13.
In this study we utilized the Surveillance, Epidemiology and End-Results (SEER) registry to identify risk factors for lymphatic spread and determine the incidence of pelvic and para-aortic lymph node metastases in patients with uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) who underwent complete surgical staging and lymph node dissection.
Nine hundred seventy-two eligible patients diagnosed between 1998 to 2009 with International Federation of Gynecology and Obstetrics (FIGO) 1988 stage IA-IVA UPSC (n=685) or UCCC (n=287) were identified for analysis. Binomial logistic regression was used to determine risk factors for lymph node metastasis, with the incidence of pelvic and para-aortic lymph node metastases reported for each FIGO primary tumor stage. The Cox proportional hazards regression model was used to determine factors associated with overall survival.
FIGO primary tumor stage was the only independent risk factor for lymph node metastasis (p<0.01). The incidence of pelvis-only and para-aortic lymph node involvement according to the FIGO primary tumor stage were as follows: IA (2.3%/3.8%), IB (7.5%/5.2%), IC (22.5%/16.9%), IIA (20.8%/13.2%), IIB (25.7%/14.9%), and III/IV (25.7%/24.3%). Prognostic factors for overall survival included lymph node involvement (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.09 to 1.85; p<0.01), patient age >60 years (HR, 1.70; 95% CI, 1.21 to 2.41; p<0.01), and advanced FIGO primary tumor stage (p<0.01). Tumor grade, histologic subtype, and patient race did not predict for either lymph node metastasis or overall survival.
There is a high incidence of both pelvic and para-aortic lymph node metastases for FIGO stages IC and above uterine papillary serous and clear cell carcinomas, suggesting a potential role for lymph node-directed therapy for these patients.
本研究利用监测、流行病学和最终结果(SEER)数据库,确定了接受全面手术分期和淋巴结清扫的子宫乳头状浆液性癌(UPSC)和子宫透明细胞癌(UCCC)患者发生淋巴转移的风险因素,并确定盆腔和腹主动脉旁淋巴结转移的发生率。
本研究纳入了 1998 年至 2009 年间诊断为国际妇产科联盟(FIGO)1988 分期 IA-IVA 期 UPSC(n=685)或 UCCC(n=287)的 972 名符合条件的患者,进行分析。采用二项逻辑回归确定淋巴结转移的风险因素,报告每个 FIGO 原发肿瘤分期的盆腔和腹主动脉旁淋巴结转移发生率。采用 Cox 比例风险回归模型确定与总生存相关的因素。
FIGO 原发肿瘤分期是淋巴结转移的唯一独立危险因素(p<0.01)。根据 FIGO 原发肿瘤分期,仅盆腔和腹主动脉旁淋巴结受累的发生率如下:IA 期(2.3%/3.8%)、IB 期(7.5%/5.2%)、IC 期(22.5%/16.9%)、IIA 期(20.8%/13.2%)、IIB 期(25.7%/14.9%)和 III/IV 期(25.7%/24.3%)。总生存的预后因素包括淋巴结受累(风险比[HR],1.42;95%置信区间[CI],1.09 至 1.85;p<0.01)、患者年龄>60 岁(HR,1.70;95%CI,1.21 至 2.41;p<0.01)和晚期 FIGO 原发肿瘤分期(p<0.01)。肿瘤分级、组织学亚型和患者种族均不能预测淋巴结转移或总生存。
FIGO 分期为 IC 期及以上的 UPSC 和 UCCC 患者发生盆腔和腹主动脉旁淋巴结转移的发生率较高,提示这些患者可能需要进行淋巴结定向治疗。